Genetic analysis beyond the causative variants, and independent of the core clinical symptoms (pyramidal signs versus ataxia), might offer a more pertinent way to approach phenotypic variability.

The US biotech’s neurological drug candidate showed a reduction in disease progression of at least 50% and the company will ...

With fresh, positive data in hand, Biohaven now believes its medicine could be the first to receive FDA approval for spinocerebellar ataxia.

Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of ...

Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Biohaven Ltd. (BHVN – Research Report) and keeping the price target ...

Shares of Biohaven climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological ...

European Commission approves OMP Designation for NLX-112 (befiradol) following compelling results in studies funded by the US Dept of De ...

Biohaven has met the main goal in a study evaluating its drug in patients with an inherited disease that mainly affects the ...

To establish whether the DNA expansion linked to spinocerebellar ataxia type 8 (SCA 8) is associated with ataxia in Scotland; to clarify the range of associated clinical phenotypes; and to compare the ...

Biohaven Ltd. reported positive results from a pivotal study using troriluzole for the treatment of patients with ...